Giovanni Barillari Selected Research

Malignant Mesothelioma

1/2023	Antitumoral effects of Bortezomib in malignant mesothelioma: evidence of mild endoplasmic reticulum stress in vitro and activation of T cell response in vivo.
1/2022	Combined treatment with inhibitors of ErbB Receptors and Hh signaling pathways is more effective than single treatment in reducing the growth of malignant mesothelioma both in vitro and in vivo.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Giovanni Barillari Research Topics

Disease

28	Neoplasms (Cancer) 02/2024 - 11/2002
10	Hemorrhage 07/2022 - 05/2006
9	Kaposi Sarcoma (Kaposi's Sarcoma) 01/2011 - 03/2002
7	Acquired Immunodeficiency Syndrome (AIDS) 01/2011 - 04/2002
6	Venous Thromboembolism 10/2020 - 10/2010
5	Disease Progression 01/2023 - 07/2010
5	Venous Thrombosis (Deep-Vein Thrombosis) 10/2020 - 01/2015
4	Rhabdomyosarcoma 01/2023 - 01/2022
4	Hemophilia A (Haemophilia) 02/2021 - 08/2011
4	Carcinoma (Carcinomatosis) 12/2020 - 05/2012
4	Pulmonary Embolism 01/2018 - 10/2010
3	Sarcoma (Soft Tissue Sarcoma) 10/2022 - 01/2022
3	Thrombosis (Thrombus) 01/2021 - 02/2014
3	Uterine Cervical Dysplasia 12/2020 - 05/2012
2	Body Weight (Weight, Body) 12/2023 - 03/2017
2	Breast Neoplasms (Breast Cancer) 02/2023 - 04/2010
2	Malignant Mesothelioma 01/2023 - 01/2022
2	Adenocarcinoma 01/2021 - 01/2011
2	HIV Infections (HIV Infection) 12/2020 - 05/2012
2	Thrombocytopenia (Thrombopenia) 11/2020 - 02/2014
2	Stroke (Strokes) 10/2020 - 01/2017
2	Atrial Fibrillation 10/2020 - 01/2017
2	Neoplasm Metastasis (Metastasis) 06/2020 - 09/2003
2	Infections 08/2011 - 11/2002
2	Pre-Eclampsia (Preeclampsia) 03/2011 - 01/2003
1	Squamous Cell Carcinoma of Head and Neck 01/2023
1	Multiple Myeloma 01/2023
1	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 01/2023
1	Neuroblastoma 11/2022
1	COVID-19 07/2022
1	Embryonal Rhabdomyosarcoma 01/2022
1	Carcinogenesis 12/2021
1	Persistent Infection 12/2021
1	Head and Neck Neoplasms (Head and Neck Cancer) 01/2021

Drug/Important Bio-Agent (IBA)

10	HIV Protease InhibitorsIBA 12/2020 - 03/2002
9	AnticoagulantsIBA 01/2021 - 10/2010
7	Matrix Metalloproteinases (MMPs)IBA 02/2024 - 01/2011
6	Proteins (Proteins, Gene)FDA Link 01/2022 - 03/2009
6	Saquinavir (Invirase)FDA Link 12/2020 - 08/2003
5	CytokinesIBA 12/2021 - 11/2002
5	Indinavir (Crixivan)FDA Link 12/2020 - 08/2003
4	Ritonavir (Norvir)FDA Link 12/2020 - 09/2003
3	RNA (Ribonucleic Acid)IBA 01/2023 - 04/2010
3	Proteasome Endopeptidase Complex (Proteasome)IBA 01/2023 - 01/2011
3	Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)IBA 11/2020 - 03/2017
3	EnzymesIBA 06/2020 - 02/2003
3	tat Gene Products (tat Protein)IBA 10/2016 - 04/2002
3	Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor)IBA 01/2011 - 06/2010
2	Biomarkers (Surrogate Marker)IBA 01/2023 - 01/2015
2	Bortezomib (Velcade)FDA Link 01/2023 - 01/2021
2	Oncogene Proteins (Oncogene Protein)IBA 10/2022 - 12/2021
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 12/2020 - 01/2015
2	Vitamin K FDA Link 01/2018 - 02/2014
2	Trans-Activators (Trans-Acting Factor)IBA 10/2016 - 04/2006
2	Blood Coagulation Factors (Coagulation Factor)IBA 08/2011 - 05/2006
2	Angiogenesis Inducing Agents (Angiogenesis Factor)IBA 08/2011 - 11/2002
2	Protease Inhibitors (Protease Inhibitor)IBA 01/2011 - 09/2003
2	Telomerase (Telomerase Reverse Transcriptase)IBA 11/2010 - 07/2010
2	Fibrinogen (Factor I)FDA Link 06/2009 - 05/2006
1	PolyphenolsIBA 02/2024
1	Metalloproteases (Metalloproteinases)IBA 02/2024
1	Focal Adhesion Protein-Tyrosine KinasesIBA 02/2024
1	plerixafor FDA Link 12/2023
1	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 12/2023
1	Immune Checkpoint InhibitorsIBA 02/2023
1	LigandsIBA 01/2023
1	NectinsIBA 01/2023
1	Chymotrypsin FDA Link 01/2023
1	Polyamine OxidaseIBA 01/2023
1	Drug CombinationsIBA 11/2022
1	Mitoxantrone (Novantrone)FDA LinkGeneric 11/2022
1	ChemokinesIBA 11/2022
1	PBI-05204IBA 01/2022
1	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2022
1	oleandrinIBA 01/2022
1	ErbB Receptors (EGF Receptor)IBA 01/2022
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 12/2021
1	von Willebrand FactorIBA 02/2021
1	Factor VIII (Coagulation Factor VIII)IBA 02/2021
1	ABO Blood-Group SystemIBA 02/2021
1	Tissue Inhibitor of Metalloproteinase-3IBA 12/2020
1	Lopinavir FDA Link 12/2020
1	Estrogens (Estrogen)FDA Link 12/2020
1	Factor Xa InhibitorsIBA 10/2020
1	Angiogenesis InhibitorsIBA 01/2020
1	Peptide Hydrolases (Proteases)FDA Link 05/2018
1	RivaroxabanIBA 03/2018
1	fibrin fragment D (D-dimer)IBA 06/2017

Therapy/Procedure

19	Therapeutics 02/2024 - 11/2002
4	Radiotherapy 01/2023 - 01/2020
3	Drug Therapy (Chemotherapy) 01/2023 - 01/2020
2	Immunotherapy 01/2023 - 11/2022
2	Highly Active Antiretroviral Therapy (HAART) 05/2012 - 09/2003
1	Intravenous Administration 01/2023
1	Lab-On-A-Chip Devices 11/2022
1	Immunomodulation 11/2022
1	Length of Stay 07/2022
1	Transplantation 06/2020
1	Deprescriptions 09/2018
1	Polypharmacy 09/2018